February 27, 2017: As the calendar turns to March, investors and biotech insiders are waiting for the FDA to rule on six therapies that will impact the bottom line of the developers, according to an analysis by RTT News.
February 27, 2017: In September 2016, Takeda set aside $15B for acquisitions, primarily in the U.S. The company said acquisitions would be in line with the company’s plan to refocus its R&D on three targeted therapeutic areas—oncology, gastroenterology and the CNS.
February 27, 2017: New company Exonics Therapeutics came out of the gate with $5M in seed financing from CureDuchenne Ventures, to harness the power of CRISPR-Cas9 genome editing tech.
February 27, 2017: Michael Gilman, who founded and sold Padlock Therapeutics, along other industry vets with backgrounds at Biogen, teamed together to launch startup Arrakis Therapeutics.